Overall, while immune cold tumors represent a difficult to treat tumor and are associated with poor patient outcome, there is encouraging data suggesting that reactivation of the tumor immunity cycle via STING agonists or targeting ENPP1 or CD73 is sufficient to increase immune cell infiltration into the tumor especially in combination with either chemotherapy or radiotherapy. This evidence concerns the gene NT5E and neoplasm.